Previous 10 | Next 10 |
Thinly traded nano cap Leap Therapeutics (NASDAQ: LPTX ) slips 10% premarket on average volume in reaction to stock purchase agreements with Lincoln Park Capital Fund, LLC. More news on: Leap Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CAMBRIDGE, Mass. , July 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into common stock purchase agreements for up to $21 million with Lincoln Park Capita...
CAMBRIDGE, Mass. , June 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli , Ph.D., Chairman, President and Chief Executive Officer, will present...
CAMBRIDGE, Mass. , May 15, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2019 . "In the first quarter, we presented i...
The following slide deck was published by Leap Therapeutics, Inc. in conjunction with this Read more ...
NetworkNewsWire Editorial Coverage : Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs u...
CAMBRIDGE, Mass. , April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli , Ph.D., Chairman, President and Chief Executive Officer, w...
Leap Therapeutics (NASDAQ: LPTX ): FY GAAP EPS of -$2.11 beats by $0.27. More news on: Leap Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass. , April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical development programs along with financial results for the fourth quarter and year...
AquaBounty Technologies (NASDAQ: AQB ) -21% on equity offering . More news on: AquaBounty Technologies, Inc., Urovant Sciences Ltd., Daré Bioscience, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...